Search research articles
Contact Us
Filters
Showing results (1-10 of 65) with videos related to
Page
of 7
Sort By:
Frontiers in Pharmacology
|
July 21, 2011
In silico toxicology - non-testing methods
Hannu Raunio
Expert Opinion on Drug Metabolism & Toxicology
|
August 23, 2006
In vitro screening of drug metabolism during drug development: can we trust the predictions?
Olavi Pelkonen, Hannu Raunio
Personalized Medicine
|
May 17, 2018
From pharmacogenomics to integrated personal omics profiling: a gap in implementation into healthcare
Carsten Carlberg, Hannu Raunio
Drug Metabolism and Drug Interactions
|
June 19, 2012
CYP2A6: genetics, structure, regulation, and function
Hannu Raunio, Minna Rahnasto-Rilla
Current Drug Metabolism
|
November 1, 2006
The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico
Miia Turpeinen, Hannu Raunio, Olavi Pelkonen
American Journal of Respiratory Cell and Molecular Biology
|
November 25, 2010
Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis
Sisko Anttila, Hannu Raunio, Jukka Hakkola
Chemico-Biological Interactions
|
February 9, 2005
Regulation of CYP3A genes in the human respiratory tract
Hannu Raunio, Jukka Hakkola, Olavi Pelkonen
European Journal of Clinical Pharmacology
|
June 23, 2006
Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies
Tiina Heikkilä, Tuula Lekander, Hannu Raunio
Duodecim; Laaketieteellinen Aikakauskirja
|
November 22, 2007
[Not Available]
Satu Mensio, Raimo Ojala, Hannu Raunio
Clinical Pharmacokinetics
|
July 12, 2011
In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions
Olavi Pelkonen, Miia Turpeinen, Hannu Raunio
Page
of 7
Search research articles
Search
Showing results (1-10 of 65) with videos related to
Sort By:
Page
of 7
Frontiers in Pharmacology
|
July 21, 2011
In silico toxicology - non-testing methods
Hannu Raunio
Expert Opinion on Drug Metabolism & Toxicology
|
August 23, 2006
In vitro screening of drug metabolism during drug development: can we trust the predictions?
Olavi Pelkonen, Hannu Raunio
Personalized Medicine
|
May 17, 2018
From pharmacogenomics to integrated personal omics profiling: a gap in implementation into healthcare
Carsten Carlberg, Hannu Raunio
Drug Metabolism and Drug Interactions
|
June 19, 2012
CYP2A6: genetics, structure, regulation, and function
Hannu Raunio, Minna Rahnasto-Rilla
Current Drug Metabolism
|
November 1, 2006
The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico
Miia Turpeinen, Hannu Raunio, Olavi Pelkonen
American Journal of Respiratory Cell and Molecular Biology
|
November 25, 2010
Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis
Sisko Anttila, Hannu Raunio, Jukka Hakkola
Chemico-Biological Interactions
|
February 9, 2005
Regulation of CYP3A genes in the human respiratory tract
Hannu Raunio, Jukka Hakkola, Olavi Pelkonen
European Journal of Clinical Pharmacology
|
June 23, 2006
Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies
Tiina Heikkilä, Tuula Lekander, Hannu Raunio
Duodecim; Laaketieteellinen Aikakauskirja
|
November 22, 2007
[Not Available]
Satu Mensio, Raimo Ojala, Hannu Raunio
Clinical Pharmacokinetics
|
July 12, 2011
In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions
Olavi Pelkonen, Miia Turpeinen, Hannu Raunio
Page
of 7